# Seminar 14: Sleep Disorders ## Psychiatry Clerkship --- ## Learning Objectives By the end of this seminar, students will be able to: 1. Describe normal sleep architecture including NREM and REM stages and their regulation by circadian and homeostatic mechanisms 2. Diagnose insomnia disorder using DSM-5 criteria and identify contributing behavioral, cognitive, and physiological factors 3. Apply the components of cognitive behavioral therapy for insomnia as the first-line treatment for chronic insomnia 4. Recognize obstructive sleep apnea and narcolepsy through their clinical features, diagnostic methods, and treatment approaches 5. Differentiate NREM and REM parasomnias and describe the clinical significance of REM sleep behavior disorder 6. Evaluate the bidirectional relationship between sleep disturbances and psychiatric disorders including depression, anxiety, and bipolar disorder --- ## Seminar Outline ### Section 1: Sleep Physiology Normal sleep architecture consists of cyclically recurring stages that serve distinct restorative functions. Stage N1 represents the lightest phase of sleep, serving as the transition from wakefulness and constituting approximately five percent of total sleep time. Stage N2, characterized by the appearance of sleep spindles and K-complexes on electroencephalography, represents the largest proportion of sleep at roughly fifty percent of total sleep time and plays a role in memory consolidation. Stage N3, also known as slow-wave or deep sleep, is defined by high-amplitude delta waves and is most prominent during the first third of the night, serving critical functions in physical restoration and growth hormone secretion. Rapid eye movement sleep is characterized by desynchronized brain activity resembling wakefulness, conjugate rapid eye movements, and skeletal muscle atonia, and is the stage most associated with vivid dreaming. Sleep cycles through these stages approximately four to six times per night in roughly ninety-minute cycles, with deeper sleep predominating early and REM sleep increasing in duration toward morning. Sleep is regulated by two complementary physiological systems that interact to determine the timing and quality of sleep. The circadian rhythm, governed by the suprachiasmatic nucleus of the hypothalamus, operates as an approximately twenty-four-hour internal clock that is synchronized to the light-dark cycle through retinal input and regulates the timing of sleep propensity, core body temperature, and hormone release. The homeostatic sleep drive represents the accumulation of sleep pressure during wakefulness, mediated in part by the buildup of adenosine in the basal forebrain, which progressively increases the drive to sleep as the duration of wakefulness extends. Melatonin, secreted by the pineal gland in response to diminishing light signals, serves as a chemical messenger signaling the onset of the biological night. Multiple neurotransmitter systems participate in sleep-wake regulation, with gamma-aminobutyric acid promoting sleep, orexin (hypocretin) promoting wakefulness, and histamine and serotonin modulating arousal states. Sleep patterns undergo characteristic changes across the lifespan that influence both normal functioning and vulnerability to sleep disorders. Infants require sixteen to seventeen hours of sleep distributed polyphasically across the day and night, with a high proportion of active sleep that gradually differentiates into recognizable REM patterns. Children consolidate sleep into a single nocturnal period of ten to eleven hours with proportionally more slow-wave sleep than adults. Adolescents require approximately nine hours of sleep but experience a biologically driven delay in circadian timing that conflicts with early school start times, creating chronic sleep insufficiency. Adults typically require seven to eight hours of consolidated nocturnal sleep. Elderly individuals experience a reduction in slow-wave sleep, increased sleep fragmentation with more frequent awakenings, an advance in circadian phase leading to earlier sleep and wake times, and an increased prevalence of sleep disorders including sleep apnea and restless legs syndrome. The relationship between sleep and overall health extends across virtually every organ system and domain of functioning. Sleep is essential for memory consolidation, with different sleep stages contributing to the processing of declarative, procedural, and emotional memories. Sleep deprivation has profound effects on mood regulation, and even partial sleep restriction produces measurable increases in negative affect, emotional reactivity, and decreased capacity for emotion regulation. Immune function is sensitive to sleep quantity and quality, with insufficient sleep associated with reduced vaccine response, increased susceptibility to infection, and elevated inflammatory markers. Metabolic consequences of poor sleep include impaired glucose tolerance, increased appetite through alterations in leptin and ghrelin, and weight gain. Cardiovascular health is adversely affected by chronic sleep insufficiency, with associations demonstrated between short sleep duration and hypertension, myocardial infarction, stroke, and overall cardiovascular mortality. Panel A: Sleep architecture diagram showing the cyclical progression through N1, N2, N3, and REM stages across a typical night with the shift from deep sleep dominance early to REM dominance later. Panel B: Two-process model of sleep regulation illustrating the interaction between circadian alerting signal and homeostatic sleep drive across the twenty-four-hour cycle. Panel C: Developmental changes in sleep architecture from infancy through old age showing total sleep duration, sleep stage proportions, and circadian timing shifts. Panel D: Systemic health consequences of sleep deprivation organized by cognitive, mood, immune, metabolic, and cardiovascular domains. ### Section 2: Insomnia Disorder Insomnia disorder as defined by the DSM-5 requires dissatisfaction with sleep quantity or quality accompanied by one or more of three specific complaints: difficulty initiating sleep, difficulty maintaining sleep with frequent or prolonged awakenings, or early morning awakening with inability to return to sleep. The sleep disturbance must cause clinically significant distress or impairment in social, occupational, educational, or other important areas of functioning. Symptoms must occur at least three nights per week and must have persisted for at least three months to meet the chronic insomnia threshold. The disorder requires that adequate opportunity and circumstances for sleep exist, distinguishing insomnia from volitional sleep restriction. The condition must not be better explained by another sleep-wake disorder, must not be attributable to the physiological effects of a substance, and must not be adequately explained by coexisting mental or medical conditions, though it may co-occur with these conditions. Insomnia is classified by the temporal pattern of sleep disturbance and by its duration. Sleep-onset insomnia refers to difficulty falling asleep at the beginning of the night, which is common in younger adults and in the context of anxiety disorders. Sleep-maintenance insomnia involves frequent or prolonged awakenings during the night and is more prevalent in middle-aged and older adults. Early morning awakening, in which the individual wakes hours before the intended time and cannot return to sleep, is a pattern often associated with depression. From a temporal perspective, acute insomnia lasting less than three months may occur in response to identifiable stressors and frequently resolves when the precipitant abates. Chronic insomnia persisting for three months or longer typically involves the development of perpetuating factors that maintain the sleep disturbance independent of the original trigger. Multiple factors contribute to the development and perpetuation of chronic insomnia, and Spielman's three-factor model provides a useful conceptual framework. Predisposing factors include a constitutional tendency toward hyperarousal, anxious temperament, and family history of insomnia. Precipitating factors are acute stressors such as medical illness, psychosocial upheaval, or environmental changes that trigger the initial insomnia episode. Perpetuating factors are the behavioral and cognitive responses to insomnia that sustain it after the original precipitant has resolved, including poor sleep hygiene such as irregular sleep schedules and excessive caffeine use, maladaptive cognitions such as worry about the consequences of poor sleep and catastrophizing, physiological hyperarousal maintained by anxiety about sleep, and conditioned arousal in which the bed and bedroom become associated with wakefulness and frustration rather than sleep. The assessment of insomnia begins with a detailed sleep history including habitual bedtime, wake time, estimated sleep-onset latency, number and duration of nocturnal awakenings, and final awakening time. A two-week sleep diary is the standard assessment tool and provides data on night-to-night variability and sleep efficiency. Validated questionnaires such as the Insomnia Severity Index quantify symptom burden and can track treatment response. Polysomnography is generally not indicated for the evaluation of uncomplicated insomnia but should be considered when there is clinical suspicion for comorbid sleep-disordered breathing, periodic limb movement disorder, or when insomnia is refractory to standard treatment. The differential diagnosis includes screening for sleep apnea through questions about snoring, witnessed apneas, and excessive daytime sleepiness; restless legs syndrome through questions about uncomfortable leg sensations at rest; and medical conditions including pain, nocturia, and hyperthyroidism. Panel A: DSM-5 diagnostic criteria for insomnia disorder showing the nine criterion elements from dissatisfaction through exclusion of other explanatory conditions. Panel B: Classification of insomnia by temporal pattern including sleep-onset, sleep-maintenance, and early morning awakening types with associated clinical contexts. Panel C: Spielman three-factor model illustrating predisposing, precipitating, and perpetuating factors and their relative contributions across the timeline from acute to chronic insomnia. Panel D: Insomnia assessment components including sleep history elements, sleep diary parameters, questionnaire instruments, and indications for polysomnography. ### Section 3: Cognitive Behavioral Therapy for Insomnia Cognitive behavioral therapy for insomnia represents the first-line treatment for chronic insomnia disorder and is recommended before pharmacological intervention by major clinical practice guidelines. CBT-I has demonstrated efficacy equal to or exceeding that of hypnotic medications in the short term, with the critical advantage of maintaining and even improving treatment gains after therapy is completed, in contrast to the rapid return of symptoms that typically follows medication discontinuation. The standard CBT-I protocol is delivered over four to eight sessions and combines behavioral, cognitive, and educational components. Digital delivery formats, including therapist-guided online programs and fully automated applications, have expanded access to this evidence-based treatment for populations unable to access trained therapists. Sleep hygiene education, while insufficient as a standalone intervention, provides the foundational behavioral recommendations that support all other CBT-I components. Maintaining a consistent wake time seven days a week is the single most important sleep hygiene recommendation, as it reinforces circadian regularity. Caffeine should be limited and ideally avoided after noon, as its stimulant effects and long half-life can interfere with sleep onset even when consumed hours before bedtime. Alcohol, though sedating initially, disrupts sleep architecture during the second half of the night and should be minimized. Regular physical exercise promotes sleep quality but should be completed at least three to four hours before the intended sleep time to avoid exercise-induced arousal. The sleep environment should be optimized to be dark, quiet, and cool, and screen exposure should be reduced in the hour before bed due to the alerting effects of both light exposure and cognitive engagement. Sleep restriction therapy is the most potent behavioral component of CBT-I and works by increasing homeostatic sleep drive and consolidating sleep. The procedure begins by calculating the patient's average total sleep time from sleep diary data and restricting the time allotted in bed to match this amount, with a minimum floor of five to six hours to avoid excessive daytime impairment. As sleep efficiency, defined as total sleep time divided by time in bed multiplied by one hundred, improves to exceed eighty-five percent, the time in bed is gradually increased in fifteen-to-thirty-minute increments. This process creates mild, temporary sleep deprivation that increases sleep pressure, reduces sleep-onset latency, and consolidates sleep into a more efficient pattern. Although patients may experience increased daytime sleepiness during the initial restriction phase, this is transient and resolves as sleep efficiency improves. Stimulus control therapy addresses the conditioned arousal that develops when the bed becomes associated with wakefulness, frustration, and sleep-related anxiety. The core instructions dictate that the bed should be used only for sleep and sexual activity, eliminating all other activities including reading, watching television, and using electronic devices. Patients are instructed to go to bed only when feeling sleepy rather than at a predetermined clock time, thereby strengthening the association between the bed and rapid sleep onset. If sleep does not occur within approximately twenty minutes or if the patient wakes during the night and cannot return to sleep within a similar interval, they should leave the bedroom and engage in a quiet, non-stimulating activity until sleepiness returns. A consistent wake time must be maintained regardless of the amount of sleep obtained, and daytime napping is eliminated to preserve the homeostatic sleep drive for the nighttime sleep period. Panel A: CBT-I as first-line treatment showing comparison of efficacy with pharmacotherapy at treatment end and at follow-up demonstrating sustained benefit of CBT-I versus relapse with medication discontinuation. Panel B: Sleep hygiene recommendations organized by schedule regularity, substance avoidance, exercise timing, and environmental optimization. Panel C: Sleep restriction therapy protocol showing initial time-in-bed calculation, sleep efficiency threshold of eighty-five percent, gradual titration process, and expected trajectory. Panel D: Stimulus control therapy rules with the physiological rationale for each instruction and expected reconditioning of the bed-sleep association. ### Section 4: Pharmacotherapy for Insomnia Benzodiazepines enhance gamma-aminobutyric acid activity at the GABA-A receptor and were among the earliest pharmacological treatments for insomnia. Triazolam, with its short half-life, is primarily useful for sleep-onset insomnia but carries risk of rebound insomnia and anterograde amnesia. Temazepam has an intermediate half-life that provides benefit for both sleep onset and sleep maintenance and remains one of the more commonly prescribed benzodiazepine hypnotics. Flurazepam has a long half-life and active metabolites that can produce next-day sedation, cognitive impairment, and an accumulation effect with repeated dosing, making it poorly suited for chronic use. All benzodiazepines carry risks of tolerance, physical dependence, withdrawal symptoms on discontinuation, and increased fall risk, particularly in older adults, and current guidelines recommend against their use as first-line or long-term therapy. The non-benzodiazepine receptor agonists, commonly known as Z-drugs, bind selectively to the alpha-1 subunit of the GABA-A receptor and were developed to offer hypnotic efficacy with a potentially improved safety profile compared to benzodiazepines. Zolpidem is the most widely prescribed hypnotic medication and is available in immediate-release, extended-release, and sublingual formulations to address different patterns of insomnia. Zaleplon has an ultra-short half-life of approximately one hour, making it suitable for middle-of-the-night use when at least four hours of bed time remain. Eszopiclone has a longer duration of action and is the only Z-drug with FDA approval for long-term use without a specified duration limit. Despite their selectivity, Z-drugs carry risks of complex sleep behaviors including sleep-walking, sleep-driving, and sleep-eating, which prompted an FDA black box warning, as well as dependence potential with prolonged use. Several other medication classes are used for insomnia, each with distinct mechanisms and clinical profiles. Trazodone, a serotonin antagonist and reuptake inhibitor, is the most commonly prescribed off-label medication for insomnia and is used at low doses of twenty-five to one hundred milligrams for its sedating properties, though evidence for its hypnotic efficacy is limited. Melatonin, available as an over-the-counter supplement, has modest evidence for improving sleep onset, particularly in circadian rhythm disorders and in older adults with diminished endogenous melatonin. Ramelteon is a melatonin receptor agonist with FDA approval for sleep-onset insomnia and carries no abuse potential or dependence risk. Low-dose doxepin at three to six milligrams is FDA-approved for sleep-maintenance insomnia and works through histamine H1 receptor antagonism. Suvorexant and lemborexant are dual orexin receptor antagonists representing a novel mechanism that reduces wake-promoting orexin signaling and are effective for both sleep onset and maintenance. Prescribing principles for insomnia pharmacotherapy emphasize short-term use, careful selection, and integration with behavioral treatment. When medications are prescribed, they should ideally be used for the shortest effective duration, and the goal of combining pharmacotherapy with CBT-I is to facilitate a transition to medication-free sleep maintenance. The lowest effective dose should be selected, with particular caution in elderly patients who are more vulnerable to sedation-related falls, cognitive impairment, and medication accumulation. Benzodiazepines should be avoided in elderly patients, and the American Geriatrics Society Beers Criteria identifies multiple sedative-hypnotics as potentially inappropriate medications in this population. When discontinuing hypnotic medications, gradual tapering is recommended to minimize withdrawal symptoms and rebound insomnia. The combination of pharmacotherapy with CBT-I during the initial treatment period, followed by gradual medication taper as behavioral strategies take effect, represents the most evidence-based approach for optimal long-term outcomes. Panel A: Benzodiazepine hypnotics organized by half-life including triazolam, temazepam, and flurazepam with clinical applications, risks, and limitations for insomnia management. Panel B: Z-drug pharmacology showing zolpidem, zaleplon, and eszopiclone with receptor selectivity, formulations, durations of action, and FDA black box warning for complex sleep behaviors. Panel C: Alternative insomnia medications including trazodone, melatonin, ramelteon, low-dose doxepin, and orexin antagonists with mechanisms, indications, and evidence levels. Panel D: Prescribing principles for insomnia pharmacotherapy showing short-term use guidelines, dose selection, geriatric precautions, tapering protocols, and integration with CBT-I. ### Section 5: Sleep-Related Breathing Disorders Obstructive sleep apnea is characterized by repeated episodes of complete or partial upper airway collapse during sleep, resulting in intermittent hypoxia, hypercapnia, and sleep fragmentation. The severity of OSA is quantified by the Apnea-Hypopnea Index, which measures the number of apneas, defined as complete cessation of airflow for at least ten seconds, and hypopneas, defined as reduced airflow with associated oxygen desaturation or arousal, per hour of sleep. An AHI of five to fifteen events per hour classifies mild OSA, fifteen to thirty events per hour indicates moderate disease, and greater than thirty events per hour constitutes severe OSA. The clinical presentation typically includes loud snoring, witnessed apneic episodes, gasping or choking during sleep, excessive daytime sleepiness, morning headaches, and nonrestorative sleep. The risk factor profile for obstructive sleep apnea reflects the interaction of anatomical, demographic, and behavioral factors. Obesity is the strongest modifiable risk factor, as excess adipose tissue in the pharyngeal region narrows the upper airway and reduces its patency during sleep. Male sex confers approximately two to three times the risk compared to females, though this disparity narrows after menopause. The prevalence of OSA increases with advancing age due to progressive loss of upper airway muscle tone. Craniofacial anatomy plays a role, with increased neck circumference, retrognathia, macroglossia, and tonsillar hypertrophy all predisposing to airway obstruction. Alcohol consumption relaxes pharyngeal musculature and can worsen the severity of existing OSA, and sedative medications including benzodiazepines and opioids similarly increase upper airway collapsibility. The consequences of untreated obstructive sleep apnea are extensive and span multiple organ systems. Cardiovascular complications are the most significant, with OSA independently associated with systemic hypertension, particularly resistant hypertension, atrial fibrillation and other arrhythmias, coronary artery disease, myocardial infarction, congestive heart failure, and stroke. Metabolic consequences include insulin resistance, type 2 diabetes, dyslipidemia, and difficulty with weight management. Neurocognitive effects encompass excessive daytime sleepiness that impairs work performance and quality of life, as well as deficits in attention, memory, and executive function. The risk of motor vehicle accidents is increased two to seven times in individuals with untreated moderate to severe OSA, making this a significant public health concern. Diagnosis of obstructive sleep apnea relies on objective sleep testing, with in-laboratory polysomnography serving as the gold standard. Polysomnography records electroencephalography, electrooculography, electromyography, airflow, respiratory effort, oxygen saturation, body position, and cardiac rhythm, providing comprehensive data for diagnosis and severity classification. Home sleep apnea testing using portable monitors that record airflow, respiratory effort, and oxygen saturation has become an accepted alternative for patients with high pretest probability and no significant comorbidities. Continuous positive airway pressure therapy is the first-line treatment for moderate to severe OSA and works by pneumatically splinting the upper airway open during sleep. Oral appliance therapy, which advances the mandible to enlarge the retrolingual airway space, is an alternative for mild to moderate OSA or for patients who cannot tolerate CPAP. Weight loss through lifestyle modification or bariatric surgery can substantially reduce OSA severity and in some cases achieve cure, and surgical options including uvulopalatopharyngoplasty or hypoglossal nerve stimulation are considered in selected cases. Panel A: Pathophysiology of obstructive sleep apnea showing upper airway collapse during sleep with AHI severity classification at mild, moderate, and severe thresholds. Panel B: Risk factor profile for OSA organized by modifiable factors including obesity and alcohol and non-modifiable factors including sex, age, and craniofacial anatomy. Panel C: Systemic consequences of untreated OSA across cardiovascular, metabolic, neurocognitive, and accident-risk domains. Panel D: Diagnostic and treatment algorithm showing polysomnography and home testing pathways leading to CPAP, oral appliance, weight loss, and surgical treatment options. ### Section 6: Central Sleep Disorders and Hypersomnias Central sleep apnea differs fundamentally from the obstructive form in that airway patency is maintained, but the brainstem fails to generate adequate respiratory drive during sleep. The most common form occurs in the setting of congestive heart failure, where Cheyne-Stokes respiration produces a crescendo-decrescendo breathing pattern with intervening central apneas. Opioid medications suppress the medullary respiratory centers and can produce central apneas, particularly at higher doses. High altitude exposure can also produce periodic breathing with central apneas during sleep. Treatment focuses primarily on addressing the underlying cause, such as optimizing heart failure management or reducing opioid doses, and adaptive servo-ventilation may be used for complex central sleep apnea, though it is contraindicated in patients with heart failure and reduced ejection fraction due to increased mortality demonstrated in clinical trials. Narcolepsy type 1 is a chronic neurological disorder caused by the selective autoimmune destruction of orexin-producing neurons in the lateral hypothalamus, resulting in a characteristic clinical tetrad. The cardinal symptom is excessive daytime sleepiness manifesting as an irresistible urge to sleep that occurs daily and may produce involuntary sleep episodes in inappropriate situations. Cataplexy, pathognomonic for type 1 narcolepsy, consists of sudden, transient episodes of bilateral muscle weakness triggered by strong emotions, particularly laughter and surprise, ranging from subtle facial weakness to complete postural collapse with preserved consciousness. Additional features include sleep paralysis, in which the individual is temporarily unable to move or speak during the transition between sleep and wakefulness, and hypnagogic or hypnopompic hallucinations, which are vivid, often frightening perceptual experiences occurring at sleep onset or upon awakening. Diagnosis requires the Multiple Sleep Latency Test demonstrating a mean sleep latency of less than eight minutes with two or more sleep-onset REM periods, or alternatively, low cerebrospinal fluid orexin levels. Narcolepsy type 2 shares the excessive daytime sleepiness of type 1 but occurs without cataplexy, which significantly complicates diagnosis due to the overlap with other causes of hypersomnolence. Patients experience the same irresistible sleepiness and may report sleep paralysis and hypnagogic hallucinations, but the absence of cataplexy removes the most clinically distinctive feature. The Multiple Sleep Latency Test diagnostic criteria are identical to type 1, requiring mean sleep latency under eight minutes and at least two sleep-onset REM periods. Cerebrospinal fluid orexin levels are usually normal in type 2 narcolepsy, suggesting a different underlying pathophysiology. The differential diagnosis for type 2 narcolepsy includes idiopathic hypersomnia, insufficient sleep syndrome, sleep-disordered breathing, medication effects, and psychiatric conditions including depression and chronic fatigue. Treatment of narcolepsy targets both excessive daytime sleepiness and cataplexy through pharmacological and behavioral approaches. For sleepiness, modafinil and armodafinil are first-line wake-promoting agents that offer sustained alertness with a favorable side-effect profile. Traditional psychostimulants including methylphenidate and amphetamines are effective alternatives when modafinil is insufficient. Sodium oxybate, the pharmaceutical preparation of gamma-hydroxybutyrate, is uniquely effective for both sleepiness and cataplexy, consolidating nocturnal sleep and reducing daytime sleep attacks when taken in two divided doses at bedtime and again two to four hours later. For cataplexy specifically, antidepressant medications with noradrenergic activity, including serotonin-norepinephrine reuptake inhibitors and tricyclic antidepressants, suppress REM sleep-related phenomena and reduce cataplexy frequency. Behavioral strategies including scheduled daytime naps of fifteen to twenty minutes can provide temporary symptom relief and complement pharmacotherapy. Panel A: Central sleep apnea pathophysiology showing absent respiratory drive with preserved airway patency, Cheyne-Stokes pattern in heart failure, and opioid-related central apneas. Panel B: Narcolepsy type 1 clinical features including sleepiness, cataplexy with emotional triggers, sleep paralysis, and hypnagogic hallucinations with orexin deficiency mechanism. Panel C: Narcolepsy type 2 diagnostic features and differential diagnosis with comparison to type 1 across cataplexy presence, orexin levels, and MSLT criteria. Panel D: Narcolepsy treatment algorithm showing modafinil for sleepiness, sodium oxybate for combined symptoms, antidepressants for cataplexy, and scheduled naps as behavioral adjunct. ### Section 7: Circadian Rhythm Sleep-Wake Disorders Circadian rhythm sleep-wake disorders arise from misalignment between the endogenous circadian timing system and the desired or required sleep-wake schedule, producing complaints of insomnia, excessive sleepiness, or both. Delayed sleep-wake phase disorder is the most common circadian disorder and is characterized by a habitual sleep-onset time that is significantly later than conventional or desired, typically falling between two and six in the morning, with a correspondingly late spontaneous wake time. Advanced sleep-wake phase disorder presents with the opposite pattern, with sleep onset occurring in the early evening and spontaneous awakening in the very early morning hours. Irregular sleep-wake rhythm disorder manifests as a temporally disorganized sleep pattern without a clearly identifiable major sleep period. Non-twenty-four-hour sleep-wake rhythm disorder, occurring most commonly in totally blind individuals who lack photic entrainment, results in a free-running circadian clock that progressively drifts out of alignment with the twenty-four-hour day. Shift work disorder and jet lag disorder represent environmentally imposed circadian misalignment. Delayed sleep-wake phase disorder is particularly prevalent among adolescents and young adults due to the convergence of biological and social factors. The pubertal delay in circadian timing, driven by changes in the sensitivity of the circadian clock to light and in the timing of melatonin secretion, pushes the natural sleep propensity window later. This biological shift interacts with social and behavioral factors including evening light exposure from electronic devices and reduced morning light exposure. The clinical consequence is an inability to fall asleep at socially conventional times despite adequate sleep drive, leading to chronic sleep deprivation when early morning obligations require waking before the circadian-preferred time. Treatment utilizes strategically timed bright light therapy in the morning to advance the circadian clock, exogenous melatonin administered in the evening approximately three to five hours before the desired sleep time to facilitate phase advance, and chronotherapy, which involves progressively delaying the sleep period around the clock until the desired schedule is achieved. Shift work disorder affects an estimated ten to forty percent of individuals who work non-standard schedules, including rotating shifts, permanent night shifts, and early morning shifts. The disorder produces insomnia during the designated sleep period and excessive sleepiness during the work shift, resulting from the misalignment between the work-imposed schedule and the endogenous circadian alerting signal. The consequences extend beyond sleep disruption to include increased risk of occupational accidents, cardiovascular disease, metabolic syndrome, gastrointestinal disorders, and mood disturbances. Treatment strategies include strategic napping before or during the shift to reduce sleepiness, bright light exposure during the work period to promote alertness, melatonin administration before the designated sleep period to facilitate sleep onset, and pharmacological wake-promotion with modafinil for individuals with significant residual sleepiness despite behavioral interventions. Light and melatonin represent the two primary chronotherapeutic tools for circadian rhythm disorders, and their effects depend critically on the timing of administration relative to the endogenous circadian phase. Morning bright light exposure advances the circadian clock, shifting the sleep period earlier, while evening light exposure delays the circadian clock, shifting sleep later. The standard therapeutic light box delivers ten thousand lux at a distance of twelve to sixteen inches for approximately thirty minutes, and dawn simulation and outdoor light exposure are alternative approaches. Exogenous melatonin administered in the evening advances the circadian rhythm, while morning administration produces a phase delay. The dose-response relationship for melatonin's chronobiotic effect is distinct from its hypnotic effect, with lower doses of 0.5 to one milligram often more effective for phase shifting than higher doses. Understanding the phase-response curve for both light and melatonin is essential for correctly timing these interventions to produce the desired direction of circadian shift. Panel A: Classification of circadian rhythm sleep-wake disorders showing delayed, advanced, irregular, non-twenty-four-hour, shift work, and jet lag types with characteristic sleep timing patterns. Panel B: Delayed sleep-wake phase disorder in adolescents showing biological clock delay, social and behavioral contributors, and treatment with morning light plus evening melatonin. Panel C: Shift work disorder prevalence, clinical consequences across health domains, and multimodal treatment approach including napping, light exposure, melatonin, and pharmacotherapy. Panel D: Phase-response curves for light and melatonin showing the relationship between timing of administration and direction of circadian phase shift with clinical application guidelines. ### Section 8: Parasomnias NREM parasomnias arise from incomplete arousal from slow-wave sleep and typically occur during the first third of the night when N3 sleep is most abundant. Sleepwalking involves complex ambulatory behavior during sleep, with the individual appearing awake but demonstrating reduced awareness, impaired judgment, and retrograde amnesia for the episode. Sleep terrors present as sudden arousal from deep sleep accompanied by a piercing scream, intense autonomic activation including tachycardia and diaphoresis, and an expression of extreme fear; despite the dramatic presentation, the individual is difficult to arouse and typically has no recollection of the event. Confusional arousals manifest as disorientation, slowed speech, and inappropriate behavior upon awakening. Sleep-related eating disorder involves compulsive eating during partial arousals, often with consumption of unusual food combinations and amnesia for the episodes. NREM parasomnias share common predisposing and precipitating factors including genetic susceptibility, sleep deprivation, fever, alcohol use, and medications that deepen sleep. REM parasomnias occur during rapid eye movement sleep and involve distinct pathophysiological mechanisms. REM sleep behavior disorder results from the loss of the normal skeletal muscle atonia that characterizes REM sleep, allowing individuals to physically enact their dreams through vocalizations and complex motor behaviors including punching, kicking, grabbing, and leaping from bed. Nightmare disorder involves disturbing dream content that produces full awakening with detailed recall of the dream, intact orientation, and difficulty returning to sleep. Isolated sleep paralysis consists of a temporary inability to move or speak during the transition between sleep and wakefulness, often accompanied by a sense of a threatening presence or pressure on the chest. The clinical significance of REM sleep behavior disorder extends beyond the immediate risks of injury, as it has emerged as one of the strongest prodromal markers for alpha-synucleinopathies. REM sleep behavior disorder merits particular clinical attention due to its strong association with neurodegenerative disease. The loss of REM atonia that underlies the disorder results from dysfunction in the pontine and medullary nuclei responsible for generating the descending inhibitory signals that normally suppress motor activity during REM sleep. Dream enactment behaviors are often vigorous and violent, with patients reporting dreams of being chased or attacked, and the risk of injury to both the patient and bed partner is substantial. The most important clinical implication is the association with alpha-synuclein-mediated neurodegenerative diseases: longitudinal studies demonstrate that greater than eighty percent of individuals with idiopathic REM sleep behavior disorder eventually develop Parkinson disease, dementia with Lewy bodies, or multiple system atrophy, often after a prodromal period of years to decades. Treatment with low-dose clonazepam at 0.25 to two milligrams at bedtime is the most established pharmacotherapy, while melatonin at three to twelve milligrams represents a safer alternative, particularly in elderly patients. Safety measures form an essential component of parasomnia management for both NREM and REM disorders. The sleep environment should be secured by removing sharp objects, furniture with hard edges, and potential weapons from the bedroom. Placing the mattress on the floor or using padded bed rails reduces the risk of injury from falling out of bed. Doors and windows should be locked or alarmed to prevent the individual from leaving the sleep environment during an episode. Addressing precipitating factors is critical and includes ensuring adequate sleep duration to minimize sleep deprivation, restricting alcohol consumption, managing stress, and reviewing medications that may trigger or worsen parasomnia events. Pharmacotherapy with clonazepam is effective for both NREM and REM parasomnias and works through different mechanisms depending on the disorder type, reducing arousals from slow-wave sleep in NREM disorders and restoring REM atonia in REM sleep behavior disorder. Panel A: NREM parasomnias including sleepwalking, sleep terrors, confusional arousals, and sleep-related eating disorder with typical timing, features, and shared predisposing factors. Panel B: REM parasomnias including REM sleep behavior disorder, nightmare disorder, and sleep paralysis with pathophysiology and distinguishing clinical characteristics. Panel C: REM sleep behavior disorder natural history showing progression from idiopathic RBD to alpha-synucleinopathy with conversion rates and prodromal timeline. Panel D: Safety measures for parasomnia management including environmental modifications, trigger avoidance, and pharmacotherapy options for NREM and REM disorders. ### Section 9: Sleep-Related Movement Disorders Restless legs syndrome is a sensorimotor disorder characterized by an urge to move the legs, usually accompanied by uncomfortable sensations described as crawling, tingling, burning, or an indescribable deep discomfort. The diagnostic criteria require that the urge to move or unpleasant sensations begin or worsen during periods of rest or inactivity, are partially or totally relieved by movement such as walking or stretching for at least as long as the activity continues, and occur exclusively or predominantly in the evening or at night. This circadian pattern distinguishes restless legs syndrome from other conditions that produce leg discomfort and reflects the influence of circadian fluctuations in dopaminergic function and iron availability. The clinical impact is significant, as symptoms frequently delay sleep onset, produce nocturnal awakenings, and result in chronic sleep deprivation, daytime fatigue, impaired concentration, and mood disturbance. The etiology of restless legs syndrome involves both primary and secondary causes that require systematic evaluation. Primary restless legs syndrome has a strong genetic basis, with multiple susceptibility loci identified in genome-wide association studies, and affected individuals often report a positive family history. Iron deficiency is the most important secondary cause and reversible contributor, as iron serves as a cofactor for tyrosine hydroxylase, the rate-limiting enzyme in dopamine synthesis, and low brain iron impairs dopaminergic function in the basal ganglia. Serum ferritin should be measured in all patients with RLS, and iron supplementation is recommended when ferritin levels fall below seventy-five nanograms per milliliter. Pregnancy is associated with a transient increase in RLS prevalence, with symptoms typically resolving after delivery. Chronic kidney disease with uremia is a well-established cause. Several medication classes can induce or exacerbate restless legs syndrome, including antidepressants, particularly selective serotonin reuptake inhibitors, first-generation antihistamines, and dopamine-blocking antiemetics. Current treatment guidelines for restless legs syndrome recommend alpha-2-delta calcium channel ligands as first-line pharmacotherapy. Gabapentin and pregabalin are preferred over dopamine agonists because they do not carry the risk of augmentation, a paradoxical worsening of symptoms characterized by earlier onset, greater intensity, and spread to previously unaffected body parts that occurs with long-term dopaminergic therapy. Iron supplementation should be initiated when ferritin levels are below seventy-five nanograms per milliliter, and intravenous iron may be more effective than oral formulations, particularly in patients with ferritin levels below thirty nanograms per milliliter. Dopamine agonists including pramipexole and ropinirole remain effective options but should be used at the lowest effective dose due to the augmentation risk, and patients should be counseled about this phenomenon and monitored regularly. In severe, refractory cases, low-dose opioid therapy may be considered, and evidence supports the use of prolonged-release oxycodone-naloxone in treatment-resistant restless legs syndrome. Periodic limb movement disorder is characterized by repetitive, stereotyped limb movements, typically involving dorsiflexion of the ankle and flexion of the knee and hip, occurring during non-REM sleep at intervals of twenty to forty seconds. While periodic limb movements of sleep are extremely common and found incidentally in many individuals, periodic limb movement disorder is diagnosed only when the movements cause clinically significant sleep disturbance or daytime impairment and are not better explained by another sleep disorder. The condition is strongly associated with restless legs syndrome, with the majority of RLS patients demonstrating periodic limb movements on polysomnography, though the reverse association is less consistent. Diagnosis requires polysomnography demonstrating a periodic limb movement index of fifteen or more per hour in adults with associated arousals and clinical symptoms. Treatment parallels that of restless legs syndrome, with alpha-2-delta ligands and dopamine agonists constituting the primary pharmacological options. Panel A: Restless legs syndrome diagnostic criteria showing the four essential features of urge to move, worsening at rest, relief with movement, and circadian pattern with clinical impact on sleep and daytime functioning. Panel B: Etiology of RLS showing primary genetic factors and secondary causes including iron deficiency, pregnancy, renal disease, and offending medications with recommended ferritin threshold. Panel C: RLS treatment algorithm showing iron supplementation for low ferritin, alpha-2-delta ligands as first-line, dopamine agonists with augmentation risk warning, and opioids for refractory cases. Panel D: Periodic limb movement disorder features showing stereotyped movement pattern, polysomnographic criteria, association with RLS, and treatment approach. ### Section 10: Sleep in Psychiatric Disorders The relationship between sleep and depression is bidirectional and clinically significant, with insomnia both predicting the development of new depressive episodes and serving as a residual symptom that increases relapse risk. Sleep disturbance is present in approximately ninety percent of individuals with major depressive disorder, most commonly as insomnia, though hypersomnia characterizes the atypical depression specifier. Polysomnographic findings in depression include decreased REM sleep latency, meaning that the first REM period occurs earlier in the night than normal, and increased REM density, reflecting a greater number of eye movements during REM sleep. These REM sleep abnormalities may represent trait markers of depression vulnerability and have been studied as potential biomarkers. Treatment of the underlying depression generally improves sleep, though persistent insomnia after remission of mood symptoms may require targeted intervention. Trazodone is commonly prescribed as an adjunctive sleep agent in patients taking activating antidepressants, though evidence for its hypnotic efficacy is limited to small studies. Anxiety disorders produce characteristic sleep disturbances that reflect the core pathophysiology of heightened arousal and threat-related cognition. Sleep-onset insomnia is the most common pattern, as the quiet, unstimulated bedtime environment allows worry and rumination to predominate. In post-traumatic stress disorder, nightmares represent a hallmark symptom and contribute substantially to sleep disruption, hyperarousal, and avoidance of sleep. The hyperarousal that characterizes many anxiety disorders manifests as difficulty disengaging from threat-monitoring cognitions and an inability to achieve the physiological relaxation necessary for sleep initiation. Treatment of anxiety-related sleep disturbance includes CBT-I adapted for the anxious patient, and prazosin, an alpha-1 adrenergic antagonist, has demonstrated efficacy for reducing trauma-related nightmares in PTSD, though recent large-scale trials have produced mixed results. Sleep disruption plays a uniquely important role in bipolar disorder, serving not merely as a symptom but as a potential trigger of mood episodes. During manic episodes, the decreased need for sleep is a cardinal feature, and it is critical to distinguish this from insomnia: the manic patient feels rested and energized after minimal sleep, whereas the insomniac patient feels fatigued and distressed. Depressive episodes in bipolar disorder may present with either insomnia or hypersomnia. Sleep deprivation, whether accidental or therapeutic, can trigger manic or hypomanic episodes in vulnerable individuals, making sleep regulation a cornerstone of bipolar disorder management. Interpersonal and social rhythm therapy specifically targets the stabilization of daily routines including sleep-wake schedules as a strategy for mood episode prevention. Sleep disturbances are prevalent in schizophrenia and other psychotic disorders, though they have historically received less clinical attention than in mood and anxiety disorders. Individuals with schizophrenia commonly demonstrate irregular sleep-wake patterns, prolonged sleep-onset latency, reduced sleep efficiency, and disruptions in circadian rhythmicity that may predate the onset of psychotic symptoms. The relationship between sleep deprivation and psychosis is well established, with acute sleep loss capable of producing perceptual disturbances, paranoid ideation, and disorganized thinking even in healthy individuals. Antipsychotic medications have variable effects on sleep architecture, with some agents such as olanzapine and quetiapine producing significant sedation and improved sleep continuity, while others may disrupt sleep through different mechanisms. Sleep deprivation may worsen existing psychotic symptoms and complicate the assessment of treatment response, underscoring the importance of addressing sleep as a component of comprehensive psychiatric care. Panel A: Sleep and depression showing bidirectional relationship, ninety percent insomnia prevalence, polysomnographic REM abnormalities, and treatment considerations including trazodone adjunct use. Panel B: Anxiety and sleep disruption showing sleep-onset insomnia in generalized anxiety, trauma nightmares in PTSD, hyperarousal mechanisms, and prazosin for nightmare treatment. Panel C: Sleep and bipolar disorder illustrating decreased need for sleep in mania versus insomnia distinction, sleep deprivation as mood episode trigger, and social rhythm therapy rationale. Panel D: Sleep disruption in psychotic disorders showing irregular patterns, sleep deprivation as psychotomimetic, antipsychotic sedation effects, and clinical management implications. --- ## Summary - Sleep architecture consists of N1, N2, N3 (slow-wave), and REM stages cycling in approximately ninety-minute periods, with deep sleep predominating early and REM increasing toward morning - Insomnia disorder requires difficulty initiating or maintaining sleep occurring at least three nights per week for at least three months with associated distress or functional impairment - CBT-I is the first-line treatment for chronic insomnia and includes sleep restriction, stimulus control, cognitive therapy, and sleep hygiene with durable benefits exceeding pharmacotherapy - Z-drugs including zolpidem and eszopiclone are effective for short-term insomnia management but carry risks of complex sleep behaviors and dependence - Obstructive sleep apnea involves repeated upper airway collapse with AHI greater than five events per hour and is treated primarily with CPAP - Narcolepsy type 1 features excessive sleepiness with cataplexy and orexin deficiency, treated with modafinil for sleepiness and sodium oxybate for combined symptoms - Delayed sleep-wake phase disorder is common in adolescents and is treated with morning bright light therapy and evening melatonin administration - REM sleep behavior disorder involves dream enactment due to loss of REM atonia and may precede Parkinson disease by years to decades - Restless legs syndrome produces an urge to move legs at rest, worsening in the evening, with alpha-2-delta ligands as first-line treatment and iron supplementation when ferritin is low - Sleep disturbances are pervasive in psychiatric disorders with insomnia common in depression and anxiety, and sleep regulation critical in bipolar disorder management --- ## Key Terms | Term | Definition | |------|------------| | Sleep architecture | The structured organization of sleep into NREM and REM stages cycling across the night | | Sleep efficiency | Total sleep time divided by total time in bed expressed as a percentage | | AHI | Apnea-Hypopnea Index; the number of apneas and hypopneas per hour of sleep used to classify OSA severity | | CPAP | Continuous Positive Airway Pressure; pneumatic splinting of the upper airway as first-line OSA treatment | | Cataplexy | Sudden bilateral loss of voluntary muscle tone triggered by strong emotion, pathognomonic for narcolepsy type 1 | | Circadian rhythm | Approximately twenty-four-hour endogenous biological cycle governed by the suprachiasmatic nucleus | | REM atonia | Normal skeletal muscle paralysis during REM sleep mediated by pontine and medullary inhibitory circuits | | CBT-I | Cognitive Behavioral Therapy for Insomnia; first-line treatment combining sleep restriction, stimulus control, and cognitive techniques | --- *This content is subject to the [MIT License](https://opensource.org/licenses/MIT). © 2024–2026 Hibbert School of Medicine.*